Search Results

You are looking at 41 - 50 of 82 items for :

  • "fertility preservation" x
  • Refine by Access: All x
Clear All
Full access

Cancer Risk Reduction Strategies for Transgender, Non-Binary, and Gender-Diverse People With Hereditary Cancer Syndromes

Presented by: Julie S. Mak and Diego Rodriguez

options—such as fertility preservation, assisted reproductive technologies, adoption, and surrogacy—in this patient population differ from those in the cisgender population. “Conversations about reproduction options can be very sensitive for transgender

Full access


ovary) for women who wish to maintain their fertility, and standard ovarian cancer debulking surgery is recommended for those not concerned about fertility preservation. On the contrary, in women diagnosed with stage II, III, or IV epithelial ovarian

Full access

Diagnosis and Management of Rectal Cancer in Patients Younger Than 50 Years: Rising Global Incidence and Unique Challenges

Daenielle Lang and Kristen K. Ciombor

unique challenges this diagnosis presents to this patient population, including considerations of fertility preservation, the economic and financial ramifications of diagnosis and treatment, and the psychosocial stressors present in these young patients

Full access

Treatment Patterns and Survival Outcomes in Patients With Breast Cancer on Medicaid, Pre- and Post-Expansion

Siran M. Koroukian, Weichuan Dong, Jeffrey M. Albert, Uriel Kim, Kirsten Eom, Johnie Rose, Cynthia Owusu, Kristine M. Zanotti, Gregory Cooper, and Jennifer Tsui

the post-expansion period implies that treatment choices in our study population may not be comparable between the pre-expansion and post-expansion periods given concerns over fertility preservation. 36 , 37 Last, our data are specific to Ohio, and

Full access

Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn III, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth (Lisa) Tracy, Tamara Vern-Gross, Michael F. Walsh, Amy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, and Miranda Hughes

also side effects associated with the salvage regimens. The NCCN Panel recommends referral for infertility risk/fertility preservation counseling for all patients treated with chemotherapy; counseling is strongly encouraged before treatment with regimen

Full access


physicians need to better address intimacy, fertility preservation, and overall sexuality,” said Ronit Yarden, PhD, MHSA, Senior Director of Medical Affairs, Colorectal Cancer Alliance. “Treatments for colorectal cancer often come with debilitating side

Full access

Breast Cancer Version 3.2014

William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar

cancer treatment should undergo consultation with a physician with expertise in fertility before initiation of chemotherapy. 47 , 50 Multiple factors must be considered when making a decision about fertility preservation, including patient preference

Full access

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

Stage I Disease Fertility preservation is an evolving field and area of active research, with many approaches being explored, and many patient- and case-specific factors to consider, especially for those with malignancies. 73 – 75 Patients who wish to

Full access

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Kimberly Davies, Matthew Barth, Saro Armenian, Anthony N. Audino, Phillip Barnette, Branko Cuglievan, Hilda Ding, James B. Ford, Paul J. Galardy, Rebecca Gardner, Rabi Hanna, Robert Hayashi, Alexandra E. Kovach, Andrea Judit Machnitz, Kelly W. Maloney, Lianna Marks, Kristin Page, Anne F. Reilly, Joanna L. Weinstein, Ana C. Xavier, Nicole R. McMillian, and Deborah A. Freedman-Cass

in approximately 9% and 3% of pediatric patients with BL and DLBCL, respectively. 41 , 42 In addition, a baseline echocardiogram or multigated acquisition scan is recommended, and fertility counseling should be offered with fertility preservation as

Full access

Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Sarah Bean, Kristin Bradley, Susana M. Campos, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Rachel Sisodia, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Nicole R. McMillian, and Jillian Scavone

typically allows for fertility preservation. 4 , 5 Types of GTD HM occurs as a result of abnormal fertilization and is characterized as complete or partial based on differences in morphology, karyotype, and malignant potential. Most complete moles (80